drugset / Trial / NCT06284564
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
Phase 2
Active not recruiting
10 enrolled
M.D. Anderson Cancer Center
Bristol-Myers Squibb · collabCancer Prevention Research Institute of Texas · collabUnited States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.
Timeline
- Start
- 2024-08-07
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evolocumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |